AI Article Synopsis
- The study examined the role of antibodies against phosphorylcholine (anti-PC) in cardiovascular disease (CVD) among 60-year-olds, focusing on different types of antibodies, particularly IgG.
- A nested case-control design was used, involving 209 CVD cases and 620 matched controls, and binding affinities of IgG1 anti-PC clones were predicted through advanced molecular techniques.
- Results indicated that IgG1 anti-PC was a stronger protective marker against CVD risks compared to IgG and IgG2, especially notable in men, while molecular docking revealed the D05 clone showed the highest binding affinity to phosphorylcholine.
Article Abstract
Aims: Antibodies against phosphorylcholine (anti-PC) are implicated as protection markers in atherosclerosis, cardiovascular disease (CVD), and other chronic inflammatory conditions. Mostly, these studies have been focused on IgM. In this study, we determined IgG, IgG1, and IgG2 anti-PC among 60-year-olds.
Methods: Based on a 7-year follow-up of 60-year-olds (2,039 men and 2,193 women) from Stockholm County, we performed a nested case-control study of 209 incident CVD cases with 620 age- and sex-matched controls. Anti-PC was determined using ELISA. We predicted the binding affinity of PC with our fully human, in-house-produced IgG1 anti-PC clones (i.e., A01, D05, and E01) using the molecular docking and molecular dynamics simulation approach, to retrieve information regarding binding properties to PC.
Results: After adjustment for confounders, IgG and IgG2 anti-PC showed some significant associations, but IgG1 anti-PC was much stronger as a protection marker. IgG1 anti-PC was associated with an increased risk of CVD below 33rd, 25th, and 10th percentile and of stroke below 33rd and 25th, and of myocardial infarction (MI) below 10th percentile. Among men, a strong association with stroke was determined below the 33rd percentile [HR 9.20, CI (2.22-38.12); = 0.0022]. D05 clone has higher binding affinity followed by E01 and A01 using molecular docking and further have been confirmed during the course of 100 ns simulation. The stability of the D05 clone with PC was substantially higher.
Conclusion: IgG1 anti-PC was a stronger protection marker than IgG anti-PC and IgG2 anti-PC and also separately for men. The molecular modeling approach helps in identifying the intrinsic properties of anti-PC clones and atomistic interactions with PC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035555 | PMC |
| http://dx.doi.org/10.3389/fcvm.2022.809007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antibodies against Phosphorylcholine-Implications for Chronic Inflammatory Diseases.
Metabolites
June 2023
IMM, Nobels Väg 13, Karolinska Institutet, 17165 Stockholm, Sweden.
Atherosclerosis and its main consequence, cardiovascular disease (CVD) are nowadays regarded as chronic inflammatory disease conditions, and CVD is the main cause of death in the world. Other examples of chronic inflammation are rheumatic and other autoimmune conditions, but also diabetes, obesity, and even osteoarthritis among others. In addition, infectious diseases can have traits in common with these conditions.
View Article and Find Full Text PDFObjective: Prevotella copri (P copri), a gut commensal, has been reported to be an immune-relevant organism in individuals with rheumatoid arthritis (RA). This study sought to evaluate anti-P copri (anti-Pc) antibody responses in our participant cohorts and to determine when in the natural history of RA such responses develop.
Methods: We analyzed serum levels of immunoglobulin A (IgA) and IgG antibodies from a 27-kd protein of P copri (anti-Pc-p27), an immunogenic P copri protein, in study participants at risk of developing RA, participants who transitioned to RA, participants with early RA (<1 year of disease), and participants with established RA, with comparisons made to their matched controls.
Antibodies Against Phosphorylcholine Among 60-Year-Olds: Clinical Role and Simulated Interactions.
Front Cardiovasc Med
April 2022
Section of Immunology and Chronic Disease, Institute of Environmental Medicine, Karolinska Institutet, Solna, Sweden.
Article Synopsis
- The study examined the role of antibodies against phosphorylcholine (anti-PC) in cardiovascular disease (CVD) among 60-year-olds, focusing on different types of antibodies, particularly IgG.
- A nested case-control design was used, involving 209 CVD cases and 620 matched controls, and binding affinities of IgG1 anti-PC clones were predicted through advanced molecular techniques.
- Results indicated that IgG1 anti-PC was a stronger protective marker against CVD risks compared to IgG and IgG2, especially notable in men, while molecular docking revealed the D05 clone showed the highest binding affinity to phosphorylcholine.
Antibodies against phosphorylcholine and protection against atherosclerosis, cardiovascular disease and chronic inflammation.
Expert Rev Clin Immunol
May 2022
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Introduction: Chronic inflammatory diseases include cardiovascular disease (CVD), atherosclerosis, rheumatic and autoimmune diseases, and others, constituting a large part of the disease burden. It is therefore of major importance to improve understanding of underlying mechanisms, prediction, and treatment.
Areas Covered: Broad fields including atherosclerosis, immunology, and inflammation are covered, through searches on PubMed and background knowledge.
Antibodies against phosphorylcholine in hospitalized versus non-hospitalized obese subjects.
Sci Rep
October 2021
Department of Clinical Sciences, Clinical Research Centre, Lund University, Room 60-12-009, Box 50332, 202 13, Malmö, Sweden.
Obesity associates with reduced life expectancy, type 2 diabetes, hypertension and cardiovascular disease, and is characterized by chronic inflammation. Phosphorylcholine (PC) is an epitope on oxidized low-density lipoprotein, dead cells and some microorganisms. Antibodies against PC (anti-PC) have anti-inflammatory properties.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!